Michal Prčina

Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial

Petr Novák, Reinhold Schmidt, Eva Kontseková et al. · The Lancet Neurology · 2016 · 298 citations

Vaccination, Alzheimer's Disease, Vaccine Development +9

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Petr Novák, Branislav Kováčech, Stanislav Katina et al. · Nature Aging · 2021 · 168 citations

Neurodegenerative Diseases, Alzheimer's Disease, Active Immunotherapy +9

FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Petr Novák, Reinhold Schmidt, Eva Kontseková et al. · Alzheimer s Research & Therapy · 2018 · 140 citations · Full text

Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans

Petronela Weisová, Ondrej Cehlár, Rostislav Škrabana et al. · Acta Neuropathologica Communications · 2019 · 53 citations · Full text

Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation

Monika Žilková, Anna Nölle, Branislav Kováčech et al. · Acta Neuropathologica Communications · 2020 · 37 citations · Full text